The VARDA and BOAZ DOTAN RESEARCH CENTER in HEMATO-ONCOLOGY
Tel-Aviv University

24 April 2022

Dear researchers, clinicians, and TAU faculty members,

The VARDA and BOAZ DOTAN RESEARCH CENTER in HEMATO-ONCOLOGY at the Tel-Aviv University was established in 2014 in order to advance research and clinical practice in the field of hemato-oncology. During 2022, the Dotan Hemato-Oncology Grant Program will grant 3, one year “Seed Awards”, for an amount of up to ~$50000 each. The grants will be devoted for translational research in the field of hematological malignancies. We encourage the submission of proposals for research that could serve as a seed for larger research projects ultimately leading to major discoveries that will drive the field of hemato-oncology research forward. The proposed research should include a testable hypothesis based on strong scientific rationale. Since the grants are to be viewed as “seed money” for new research ventures they may also be given to a project with very little or no preliminary results. While potential clinical relevance is important, clinical trials will not be supported.

These grants are especially directed to investigators at the beginning of their research career. The committee strongly encourage joint projects carried out by a physician and an academic researcher, at least one of them in relatively early stage of his or her career.

Eligibility:

1. The submitting principal investigator (PI) must be a Tel-Aviv University faculty member or a researcher in a Tel-Aviv University-affiliated hospital and a member of the Cancer Biology Research Center (CBRC). Junior clinical faculty members (Instructors) are encouraged to apply.
2. Since we prioritize supporting early career investigators, at the time of submission, the PI must be no more than seven years from the completion of residency or fellowship or (for university investigators) not more than 7 years from receiving his/her first academic appointment.
3. A young physician who has no academic degree may submit a grant together with another PI with an academic degree as long as it is clear from the content of the grant that the young physician is the actual PI.
4. A PI can hold an academic degree up to Senior Lecturer
5. Collaborating investigators (CIs) may be from other institutions in Israel or abroad. The program encourages collaborations between clinicians and basic scientists. However, the research must be conducted in Israel at TAU or at the TAU affiliated medical centers. Money provided by the grant can be spent only in TAU institutions or affiliated medical centers. There can be only one PI for each proposal. An investigator may submit only one application as a PI. An investigator may be named in several applications but may receive funding (as PI or CI) for only one project. A PI on the regular on-going CBRC hemato-oncology research grant program is not eligible for an IA grant.
6. Previous grantees of Dotan grant program can apply as long as the previous project is completed and both scientific and financial reports were submitted.
Applicants should submit an up to 4-page proposal excluding references and budget (English, font: Arial 11/Times New Roman 12, line spacing: 1.5) including:

- **Project Title** (only one line, up to a maximum of 100 characters, not including spaces) on page 1.
- **Principal Investigator** (name, academic position and affiliation); **CIs** (if exist) (name, academic position and affiliation) on page 1.
- **Abstract** (not exceeding 300 words) on page 1.
- **Scientific Background and preliminary results** (if exist).
- **Specific aims**
- **Experimental design.**
- **Significance** (not exceeding 300 words).

In additional separate pages, the applicants should provide:

- **Cited bibliography.**
- **Itemized budget** and budget justification
- **A short CV and list of publications during the past 5 years** (NIH format up to 4 pages)
- **Other sources of support** (existing or pending). If your project is partially supported by other source, please explain the need for additional funding
- **Available research resources.** Lab space and availability of infrastructure required to carry out the proposed research.

The entire application, proposal+ additional documents, should be submitted as one PDF file.

- In a separate document please send your request to exclude reviewers (potential conflict of interest).
- **Review process**: Each application will be reviewed by a Scientific Review Panel of the Dotan committee and by external peer reviewers. The application will be evaluated for relevance of the research to hematological malignancies, scientific and/or clinical content and significance as well as originality and innovation and appropriateness of the methodology.

**Deadline** for proposal submission: **30/05/2022 Noon.**

Funding of selected projects will begin: **Oct 2022**

**Proposals should be submitted electronically to:**

Dr. Judith Ben-Porath
Operations and Scientific Manager
Dotan Research Center in Hemato-Oncology
Tel-Aviv University
03-6407322 judithbp@tauex.tau.ac.il

Submission email should include in the subject line:

**Dotan seed grants 2022 - Name of PI**

Proposals not written in accordance with the requested format will not be considered.

Upon submission, Dr. Ben-Porath will send an electronic confirmation of receipt.

Sincerely,

Prof. Shai Izraeli

Chair – Varda and Boaz Dotan Research Center in Hemato-Oncology, Tel-Aviv University